Thus, as with any new treatment modality, caution is required in the follow-up of patients receiving TNF blocker treatment, since new side effects and complications are continuously being reported.

Researchers separated biologics targeting IL-12, IL-23, and IL-17 from anti-TNF biologics ... Users experienced 8.9 infections per 100 person-years, with a nearly threefold increased risk compared ...